In light of the structural and interactive complexity of BRCA1/2, international collaborations will not only continue to improve our understanding of BRCA1/2 mutations and how mutation type and location influence breast and ovarian cancer risks (Figures 3 and 4) (71–73) but also help devise novel, targeted testing panels that can potentially support specific population-based genetic testing, similar to the Ashkenazi Jewish population. The gene discussed is BRCA1; the disease is ovarian carcinoma.